Australia - English - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - tibolone, quantity: 2.5 mg - tablet, uncoated - excipient ingredients: magnesium stearate; ascorbyl palmitate; potato starch; lactose monohydrate - short-term treatment of symptoms resulting from the natural or surgical menopause in post menopausal women. second line therapy for the prevention of bone mineral density loss in postmenopausal women at high risk of future osteoporotic fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of bone mineral density loss. after careful selection of users, xyvion should be prescribed for the shortest duration consistent with treatment goals. review the need for continuation of treatment after 6 months, taking into account the risk-benefit ratio for the individual user at the moment (including cardiovascular disease and breast cancer, refer clinical trials and precautions). xyvion should only be continued for as long as the benefit outweighs the risks.

Australia - English - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - ganirelix, quantity: 0.5 mg/ml - injection, solution - excipient ingredients: mannitol; acetic acid; sodium hydroxide; water for injections - for the prevention of premature luteinisation and ovulation in patients undergoing controlled ovarian stimulation, followed by oocyte pick up and assisted reproductive techniques.

Australia - English - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - tibolone, quantity: 2.5 mg - tablet, uncoated - excipient ingredients: magnesium stearate; potato starch; lactose monohydrate; ascorbyl palmitate - short-term treatment of symptoms resulting from the natural or surgical menopause in post menopausal women. second line therapy for the prevention of bone mineral density loss in postmenopausal women at high risk of future osteoporotic fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of bone mineral density loss. after careful selection of users, livial should be prescribed for the shortest duration consistent with treatment goals. review the need for continuation of treatment after 6 months, taking into account the risk-benefit ratio for the individual user at the moment (including cardiovascular disease and breast cancer, refer clinical trials and precautions). livial should only be continued for as long as the benefit outweighs the risks.

Australia - English - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - etonogestrel, quantity: 68 mg - implant - excipient ingredients: magnesium stearate; barium sulfate; vinyl acetate; octadecyl 3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionate; isododecane; ethylene/vinyl acetate copolymer - contraception (removed and replaced every three years to ensure continued contraceptive efficacy)

Australia - English - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - ethinylestradiol, quantity: 2.7 mg; etonogestrel, quantity: 11.7 mg - drug delivery system, vaginal - excipient ingredients: magnesium stearate; vinyl acetate; octadecyl 3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionate; isododecane; ethylene/vinyl acetate copolymer - nuvaring is for use for contraception.

Australia - English - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - follitropin beta, quantity: 833 iu/ml - injection, solution - excipient ingredients: sucrose; sodium citrate dihydrate; polysorbate 20; benzyl alcohol; methionine; hydrochloric acid; sodium hydroxide; water for injections - female: anovulatory infertility and; controlled ovarian hyperstimulation to induce the development of multiple follicles in medically assisted reproduction programs (e.g. in vitro fertilisation and related procedures). male: for the treatment of deficient spermatogenesis due to hypogonadotrophic hypogonadism.

Australia - English - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - follitropin beta, quantity: 833 iu/ml - injection, solution - excipient ingredients: sucrose; sodium citrate dihydrate; polysorbate 20; benzyl alcohol; methionine; hydrochloric acid; sodium hydroxide; water for injections - in the female: anovulatory infertility and; controlled ovarian hyperstimulation to induce the development of multiple follicles in medically assisted reproduction programs (e.g. in vitro fertilisation and related procedures). in the male: for the treatment of deficient spermatogenesis due to hypogonadotrophic hypogonadism.

Australia - English - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - follitropin beta, quantity: 833 iu/ml - injection, solution - excipient ingredients: sucrose; sodium citrate dihydrate; polysorbate 20; benzyl alcohol; methionine; hydrochloric acid; sodium hydroxide; water for injections - in the female: anovulatory infertility and; controlled ovarian hyperstimulation to induce the development of multiple follicles in medically assisted reproduction programs (e.g. in vitro fertilisation and related procedures). in the male: for the treatment of deficient spermatogenesis due to hypogonadotrophic hypogonadism.

Australia - English - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - rizatriptan benzoate, quantity: 7.265 mg - wafer - excipient ingredients: gelatin; aspartame; glycine; mannitol; flavour - for the acute relief of migraine in patients who have a stable, well-established pattern of migraine symptoms.

Israel - English - Ministry of Health

organon pharma israel ltd., israel - finasteride - film coated tablets - finasteride 1 mg - finasteride - finasteride - propecia is indicated for the treatment of men with male pattern hair loss (androgenetic alopecia) to increase hair growth and prevent further hair loss